|
| Exchange Disseminated Time 17/01/2017 18:48:01 | Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on February 02, 2017, to consider and approve the Company's Unaudited Financial Statements for the Third Quarter and Nine months ended December 31, 2016 (Q3).
Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 26, 2016 to February 06, 2017 (both days inclusive) for the purpose of approval of Unaudited Financial Statements for the Third Quarter and Nine months ended December 31, 2016. |
|
|